{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6478a825654260001190a7cb/691cd589b958098159dd00f4?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Big deals in Big Pharma","description":"<p>The battle between Novo Nordisk and Pfizer to acquire Metsera is over. But is this merger a sign of strength or weakness for the industry? Today on the show, Rob Armstrong talks with US finance editor James Fontanella-Khan about the pressures on drug companies from Washington and the market. Also they go long Nasdaq and short Nasdaq.&nbsp;</p><p><br></p><p>For a free 30-day trial to the Unhedged newsletter go to: <a href=\"https://www.ft.com/unhedgedoffer\" rel=\"noopener noreferrer\" target=\"_blank\">https://www.ft.com/unhedgedoffer</a>.</p><p><br></p><p>You can email Robert Armstrong and Katie Martin at <a href=\"mailto:unhedged@ft.com\" rel=\"noopener noreferrer\" target=\"_blank\">unhedged@ft.com</a>.</p><p><br></p><p><a href=\"https://www.ft.com/content/fb60908a-d54f-44a2-824e-8c0a43d1645a\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Read a transcript of this episode on FT.com</strong></a></p>","author_name":"Financial Times & Pushkin Industries"}